证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-085 海南葫芦娃药业集团股份有限公司 关于与关联方签署技术合作关联交易事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于2025年10月18日披露了 《关于拟与关联方签署技术合作开发合同暨关联交易的公告》（公告编号：2025-079）， 公司拟与杭州康领先医药科技有限公司（以下简称 "康领先"）签署《技术合作开发 合同》，共同开发 "昂丹司琼口溶膜（4mg、8mg）" 及 "依达拉奉右莰醇注射用浓 溶液（5ml：依达拉奉 10mg 与右莰醇 2.5mg）" 两个项目，合同金额预估分别为910 万元和215万元，共计1,125万元。 一、关联交易进展情况 公司于近日与关联方康领先就上述两个技术合作开发项目正式签署了《技术合作开 发合同》，合同主要内容如下： 1、交易内容 甲方：海南葫芦娃药业集团股份有限公司 乙方：杭州康领先医药科技有限公司 第一条 本项目合作的内容 按现行《药品注册管理办法》及 ...

Core Viewpoint - ST HuLuWa (605199.SH) reported its Q3 2025 results, highlighting a significant institutional ownership structure with 63.01% of shares held by three institutional investors, although this represents a slight decline from the previous quarter [1] Group 1: Institutional Ownership - As of October 30, 2025, three institutional investors disclosed holding a total of 252 million shares of ST HuLuWa, which constitutes 63.01% of the company's total share capital [1] - The institutional investors include Hainan HuLuWa Investment Development Co., Ltd., Zhejiang FuWang JuDe Health Development Co., Ltd., and Hangzhou ZhongJiaRui Management Partnership (Limited Partnership) [1] - Compared to the previous quarter, the total institutional ownership percentage decreased by 0.79 percentage points [1]

Core Viewpoint - The company, Hainan Huluwa Pharmaceutical Group Co., Ltd., is under risk warning due to a negative internal control audit report for the year 2024, leading to its stock being marked with "ST" starting April 30, 2025 [24][25][23]. Financial Data - The company has not conducted an audit for the third-quarter financial report [3][10]. - The financial data for the third quarter and the first nine months of 2025 are presented in RMB, but specific figures are not disclosed in the provided documents [11][12]. Internal Control and Compliance Measures - The company has established a special rectification team led by the chairman to address issues highlighted in the internal control audit report, focusing on areas such as research and development process management and financial management [25][26]. - Continuous internal self-inspections are being conducted to strengthen internal control management, including risk assessments of newly signed contracts [26][27]. - The company is enhancing its governance structure and compliance management, responding to regulatory requirements, and improving the quality of information disclosure [27][28]. Board Meeting and Management Changes - The company held its second temporary board meeting of 2025 on October 30, where it approved the third-quarter report and appointed Liu Quanguo as the new vice president [17][20][22]. - The meeting was attended by all seven board members, and the resolutions were passed unanimously [18][19]. Investor Communication - An investor performance briefing is scheduled for November 12, 2025, to discuss the third-quarter results and address investor inquiries [30][31]. - Investors can submit questions in advance through the designated channels before the briefing [32][34].

Group 1 - ST HuLuWa announced the convening of its fourth board meeting for 2025 on October 30, 2025, in Haikou, Hainan Province, to discuss the appointment of a vice president and other documents [1] - For the year 2024, ST HuLuWa's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1]

Group 1 - The company ST HuLuWa has appointed Liu Quanguo as the vice president, with a term aligned with the fourth board of directors [1] - The company's revenue structure for the year 2024 is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1]

Company Overview - ST HuLuWa, established on June 22, 2005, and listed on the Shanghai Stock Exchange on July 10, 2020, is a high-tech enterprise engaged in the research, production, and sales of pharmaceuticals, with a strong competitive edge in the pediatric medicine sector [1] Financial Performance - For Q3 2025, ST HuLuWa reported revenue of 683 million yuan, ranking 49th out of 69 in the industry. The industry leader, Baiyunshan, achieved revenue of 61.606 billion yuan, while the industry average was 3.755 billion yuan [2] - The company's net profit for the same period was -7.5472 million yuan, placing it 56th in the industry. The top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan, with the industry average at 447 million yuan [2] Profitability and Debt - As of Q3 2025, ST HuLuWa's debt-to-asset ratio was 73.72%, an increase from 68.11% year-on-year, significantly higher than the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 40.43%, down from 50.06% year-on-year and below the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.59% to 27,300, while the average number of circulating A-shares held per account increased by 15.73% to 14,700 [5] Executive Compensation - The chairman, Liu Jingping, received a salary of 1.4 million yuan in 2024, a decrease of 6,000 yuan from 2023 [4]

Group 1 - The company HuLuWa reported a significant decline in revenue for the first three quarters, with total revenue of 682,719,912.56 yuan, representing a year-on-year decrease of 33.88% [1] - The net profit attributable to shareholders of the listed company was -11,213,924.18 yuan, indicating a loss [1] Group 2 - Among the top ten circulating shareholders, new entrants include Su Mei, Chen Kehua, Fang Bo, and Wu Jun [2]

会议召开方式：上证路演中心网络互动 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-083 海南葫芦娃药业集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 12 日 （星期三） 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo. com/） 投资者可于 2025 年 11 月 05 日 （星期三） 至 11 月 11 日 （星期二）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 huluwa@huluwayaoy e.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季 度经营成果、财务状况，公司 ...

特此公告。 海南葫芦娃药业集团股份有限公司董事会 2025 年 10 月 31 日 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-082 海南葫芦娃药业集团股份有限公司 关于聘任副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开公司第四届董事会 2025 年第二次临时会议，审议通过了《关于聘任副总 经理的议案》，按照《公司法》《公司章程》等有关规定，经公司总经理提名，董 事会提名委员会资格审查，董事会同意聘任刘全国先生担任公司副总经理，任期 与第四届董事会任期一致。 1 附： 刘全国，男，1966 年出生，中国国籍，无境外永久居留权，本科学历，执业 药师、正高级制药工程师，海南省自由贸易港 D 类人才。曾获海南省科技进步奖二 等奖、中国专利优秀奖，海南省专利金奖等。1990 年 9 月至 1996 年 5 月，担任阜 新中药厂实验室主任；1996 年 5 月至 1999 年 9 月，担任海南回元堂药业有 ...

海南葫芦娃药业集团股份有限公司 第四届董事会 2025 年第二次临时会议决议公告 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-081 （五）本次董事会会议由董事长刘景萍女士主持，公司全体高级管理人员列席 会议。 二、董事会会议审议情况 （一）审议通过了《关于公司 2025 年第三季度报告的议案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海 南葫芦娃药业集团股份有限公司 2025 年第三季度报告》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第四届董事会 2025 年第二次临时会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关 规定，会议合法有效。 （二）会议通知于 2025 年 10 月 24 日以通讯方式发出。 （三）会议于 2025 年 10 月 30 日在海南省海口市秀英区安读一路 30 号公司会 议室以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 ...